Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs

Infection and Immunity

Volumn 65, Issue 12, 1997, Pages 5171-5175

  Little, S F ^a   Ivins, B E ^a   Fellows, P F ^a   Friedlander, A M ^a  

^a Dept of Immunol and Molec Biology Bldg 1425 U States Army Med R   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; BACTERIAL ANTIGEN; BACTERIAL VACCINE; IMMUNOGLOBULIN G1; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; POLYCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; CONTROLLED STUDY; FEMALE; GUINEA PIG; INFECTION PREVENTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LETHAL GENE; NONHUMAN; PASSIVE IMMUNIZATION; PLASMID; PRIORITY JOURNAL;

EID: 0030785493     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.12.5171-5175.1997     Document Type: Article

References (32)

1. Beall, F. A., M. J. Taylor, and C. B. Thorne. 1962. Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J. Bacteriol. 83:1274-1280.
2. Belton, F. C., and R. E. Strange. 1954. Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production. Br. J. Exp. Pathol. 35:144-152.
3. Fish, D. C., B. G. Mahlandt, J. P. Dobbs, and R. E. Lincoln. 1968. Purification and properties of in vitro-produced anthrax toxin components. J. Bacteriol. 95:907-918.
4. Friedlander, A. M. 1986. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261:7123-7126.
5. Gordon, V. M., S. H. Leppla, and E. L. Hewlett. 1988. Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect. Immun. 56:1066-1069.
6. Green, B. D., L. Battisti, T. M. Koehler, C. B. Thorne, and B. E. Ivins. 1985. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun. 49:291-297.
7. Hambleton, P., and P. C. B. Turnbull. 1990. Anthrax vaccine development: a continuing story. Adv. Biotechnol. Processes 13:105-122.
8. Hansen, M. B., S. E. Nielsen, and K. Berg. 1989. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119:203-210.
9. Henderson, D. W., S. Peacock, and F. C. Belton. 1956. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J. Hyg. 54:28-36.
10. Ivins, B. E., and S. L. Welkos. 1988. Recent advances in the development of an improved, human anthrax vaccine. Eur. J. Epidemiol. 4:2-19.
11. Ivins, B. E., S. L. Welkos, S. F. Little, M. H. Crumrine, and G. O. Nelson. 1992. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun. 60:662-668.
12. Ivins, B. E., P. F. Fellows, S. L. Welkos, and M. L. Pitt. 1993. Experimental anthrax vaccines: efficacy studies in guinea pigs, abstr. E-104, p. 160. In Abstracts of the 93rd General Meeting of the American Society for Microbiology 1993. American Society for Microbiology, Washington, D.C.
13. Ivins, B. E., P. F. Fellows, and G. O. Nelson. 1994. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine 12:872-874.
14. Klein, F., D. R. Hodges, B. G. Mahlandt, W. I. Jones, B. W. Haines, and R. E. Lincoln. 1962. Anthrax toxin: causative agent in the death of rhesus monkeys. Science 138:1331-1333.
15. Klimpel, K. R., N. Arora, and S. H. Leppla. 1994. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Microbiol. 13:1093-1100.
16. Kochi, S. K., G. Schiavo, M. Mock, and C. Montecucco. 1994. Zinc content of the Bacillus anthracis lethal factor. FEMS Microbiol. Lett. 124:343-348.
17. Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 79:3162-3166.
18. Leppla, S. H. 1991. The anthrax toxin complex, p. 277-302. In J. E. Alouf and J. H. Freer (ed.), Sourcebook of bacterial protein toxins. Academic Press, New York, N.Y.
19. Lincoln, R. E., J. S. Walker, F. Klein, and B. W. Haines. 1964. Anthrax. Adv. Vet. Sci. 9:327-368.
20. Little, S. F., S. H. Leppla, and E. Cora. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56:1807-1813.
21. Little, S. F., S. H. Leppla, and A. M. Friedlander. 1990. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect. Immun. 58:1606-1613.
22. Little, S. F., B. E. Ivins, P. Fellows, and A. M. Friedlander. 1994. Passive protection of guinea pigs with monoclonal antibodies against Bacillus anthracis infection, abstr. E-64, p. 154. In Abstracts of the 94th General Meeting of the American Society for Microbiology 1994. American Society for Microbiology, Washington, D.C.
23. Little, S. F., S. H. Leppla, J. W. Burnett, and A. M. Friedlander. 1994. Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies. Biochem. Biophys. Res. Commun. 199:676-682.
24. Little, S. F., J. M. Novak, J. R. Lowe, S. H. Leppla, Y. Singh, K. R. Klimpel, B. C. Lidgerding, and A. M. Friedlander. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142:707-715.
25. Mikesell, P., B. E. Ivins, J. D. Ristroph, and T. M. Dreier. 1983. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect. Immun. 39:371-376.
26. Sanchez, A., D. Y. Pifat, R. H. Kenyon, C. J. Peters, J. B. McCormick, and M. P. Kiley. 1989. Junin virus monoclonal antibodies: characterization and cross-reactivity with other arenaviruses. J. Gen. Virol. 70:1125-1132.
27. SAS Institute. 1989. SAS/STAT user's guide, version 6, 4th ed., vol. 2. SAS Institute, Inc., Cary, N.C.
28. Smith, H., J. Keppie, and J. L. Stanley. 1955. The chemical basis of the virulence of Bacillus anthracis. V. The specific toxin produced by B. anthracis in vivo. Br. J. Exp. Pathol. 36:460-472.
29. Stanley, J. L., and H. Smith. 1961. Purification of factor I and recognition of a third factor of the anthrax toxin. J. Gen. Microbiol. 26:49-66.
30. Turnbull, P. C. B., S. H. Leppla, M. G. Broster, C. P. Quinn, and J. Melling. 1988. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med. Microbiol. Immunol. 177:293-303.
31. Uchida, I., T. Sekizaki, K. Hashimoto, and N. Terakado. 1985. Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid. J. Gen. Microbiol. 131:363-367.
32. Welkos, S. L., and A. M. Friedlander. 1988. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog. 5:127-139.